Trademark: 86920161
Word
CALISIANT
Status
Dead
Status Code
606
Status Date
Tuesday, June 30, 2020
Serial Number
86920161
Mark Type
4000
Filing Date
Thursday, February 25, 2016
Published for Opposition
Tuesday, April 18, 2017
Abandoned Date
Tuesday, June 30, 2020

Trademark Owner History
Allergan Sales, LLC - Owner At Publication

Classifications
5 Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
The wording "CALISIANT" has no meaning in a foreign language.

Trademark Events
Jun 30, 2020
Abandonment Notice E-Mailed - No Use Statement Filed
Jun 30, 2020
Abandonment - No Use Statement Filed
Dec 6, 2019
Notice Of Approval Of Extension Request E-Mailed
Dec 5, 2019
Extension 5 Granted
Dec 3, 2019
Extension 5 Filed
Dec 5, 2019
Case Assigned To Intent To Use Paralegal
Dec 3, 2019
Teas Extension Received
Mar 19, 2019
Notice Of Approval Of Extension Request E-Mailed
Mar 15, 2019
Extension 4 Granted
Mar 15, 2019
Extension 4 Filed
Mar 15, 2019
Teas Extension Received
Nov 3, 2018
Notice Of Approval Of Extension Request E-Mailed
Nov 1, 2018
Extension 3 Granted
Nov 1, 2018
Extension 3 Filed
Nov 1, 2018
Teas Extension Received
Jun 7, 2018
Notice Of Approval Of Extension Request E-Mailed
Jun 5, 2018
Extension 2 Granted
Jun 5, 2018
Extension 2 Filed
Jun 5, 2018
Teas Extension Received
Nov 17, 2017
Notice Of Approval Of Extension Request E-Mailed
Nov 15, 2017
Extension 1 Granted
Nov 15, 2017
Extension 1 Filed
Nov 15, 2017
Teas Extension Received
Jun 13, 2017
Noa E-Mailed - Sou Required From Applicant
Apr 18, 2017
Official Gazette Publication Confirmation E-Mailed
Apr 18, 2017
Published For Opposition
Mar 29, 2017
Notification Of Notice Of Publication E-Mailed
Mar 16, 2017
Law Office Publication Review Completed
Mar 3, 2017
Assigned To Lie
Feb 10, 2017
Approved For Pub - Principal Register
Feb 10, 2017
Teas/Email Correspondence Entered
Feb 10, 2017
Correspondence Received In Law Office
Feb 1, 2017
Assigned To Lie
Jan 14, 2017
Teas Change Of Correspondence Received
Jan 13, 2017
Notice Of Revival - E-Mailed
Jan 12, 2017
Teas Response To Office Action Received
Jan 12, 2017
Petition To Revive-Granted
Jan 12, 2017
Teas Petition To Revive Received
Dec 22, 2016
Abandonment Notice Mailed - Failure To Respond
Dec 21, 2016
Abandonment - Failure To Respond Or Late Response
May 25, 2016
Notification Of Non-Final Action E-Mailed
May 25, 2016
Non-Final Action E-Mailed
May 25, 2016
Non-Final Action Written
May 25, 2016
Assigned To Examiner
Mar 1, 2016
New Application Office Supplied Data Entered In Tram
Feb 29, 2016
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24